T-MAXIMUM Biotech

T-MAXIMUM Biotech is dedicated to developing universal cell therapies, positioning cell therapy as the ultimate form of medicine and exploring treatments for "incurable" diseases. The team consists of renowned experts in the fields of immunotherapy and gene editing, as well as seasoned professionals from the biopharmaceutical industry. The company's core technology platform, gene-edited allogeneic immune cell therapy, employs a proprietary 3.0 version approach that addresses HVGR and GvHD to enable universal allogeneic CAR-T cell treatment. This allows allogeneic CAR-T cells to persist longer in patients, achieving optimal therapeutic outcomes. The technology platform has reached an internationally leading level.